Glioma Treatment Market Analysis 2023-2032: Size, Restraints, Drivers, and Trends

Spread the love

The Glioma Treatment Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Glioma Treatment Market:

https://www.thebusinessresearchcompany.com/report/glioma-treatment-global-market-report

According to The Business Research Company’s Glioma Treatment Global Market Report 2024, The glioma treatment market size has grown strongly in recent years. It will grow from $4.7 billion in 2023 to $5.03 billion in 2024 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to risen incidence of gliomas, advancements in molecular understanding, evolution of standard therapies, clinical trials and research progress, improved imaging and diagnostic techniques.

The glioma treatment market size is expected to see strong growth in the next few years. It will grow to $6.4 billion in 2028 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to personalized therapies and biomarker discovery, immunotherapeutic advancements, integration of targeted therapies, emergence of novel therapeutic platforms, collaborative research initiatives. Major trends in the forecast period include blood-brain barrier penetrating agents, liquid biopsy for monitoring, focus on quality of life and supportive care, genetic and molecular subtyping, patient advocacy and involvement.

The rise in brain and CNS tumor incidence is expected to propel the growth of the glioma treatment market going forward. Brain and spinal cord tumors are uncontrolled masses of abnormal brain or central nervous systems. Glioma treatment is used in brain and spinal cord cancer to destroy any remaining cancer cells or parts of the tumor after surgery. For instance, in August 2021, according to the American Cancer Society, a US-based non-profit organization dedicated to eliminating cancer, it is estimated that 24,530 malignant tumors and 59,040 nonmalignant tumors will be identified with brain and other CNS cancers in the United States in 2021, accounting for 83,570 cases, and 18,600 deaths from the disease. Therefore, the rise in the incidence of brain and spinal cord tumors is driving the growth of the glioma treatment market.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=10689&type=smp

The glioma treatment market covered in this report is segmented –

1) By Type: Low-Grade, High-Grade

2) By Disease: Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Other Diseases

3) By Route Of Administration: Oral, Parenteral, Other Routes

4) By Treatment: Surgery, Radiation Therapy, Chemotherapy, Targeted Drug Therapy, Other Treatments

5) By End-User: Hospitals, Specialty Clinics, Other End Users

Product innovation is a key trend gaining popularity in the glioma treatment market. Major companies operating in the glioma treatment market are adopting new innovative products to sustain their position in the market. For instance, in November 2021, Daiichi Sankyo Company Limited, a Japan-based pharmaceutical company, launched Delytact, a cancer-fighting virus and the world’s first oncolytic virus therapy for brain cancer. Its viral genome carries three triple mutations that enhance and selectively replicate in cancer cells and aid in treating malignant glioma.

The glioma treatment market report table of contents includes: